Silo Pharma’s SPU-21 Treatment for Autoimmune Disease Awarded US Patent
Silo Pharma, Inc. recently announced the US Patent and Trademark Office (USPTO) has issued US Patent No. 16/825,371 titled Peptide-Targeted Liposomal Delivery for Treatment, Diagnosis, and Imaging of Diseases and Disorders. The new patent claims cover the company’s portfolio drug SPU-21, a peptide-guided anti-arthritis drug, as a method of selectively targeting inflamed synovial tissue. SPU-21 has been shown to inhibit arthritic progression in a preclinical animal model.
Eric Weisblum, Chief Executive Officer of Silo Pharma, said “Our SPU-21 liposomal homing peptides, licensed from the University of Maryland, Baltimore, are able to identify markers of arthritic inflammation in joints and have potential for the development of fusion imaging molecules and/or nanoparticles to study arthritic pathogenesis. The expanded claims in this new patent grant reinforce protection for our ongoing development of SPU-21 guided delivery of targeted psilocybin as a therapeutic agent for rheumatoid arthritis (RA), our initial indication.”
An estimated 1.3 million US adults suffer from RA, the most common autoimmune disease in US. The US market for RA drugs is expected to generate $63 billion by 2027.
Silo Pharma. Inc. is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer’s disease, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the healthcare industry. For more information, visit www.silopharma.com
Total Page Views: 844
